e-ISSN: 0975-9506, p-ISSN: 2961-6093

Available online on www.ijpqa.com

International Journal of Pharmaceutical Quality Assurance 2026; 17(1); 70-76

Original Research Article

Age-Related Macular Degeneration and Inherent Challenges of Drug Delivery to Posterior Segment of Eye Due to Ocular Barriers

Vivek Motewar[1], Jayesh K. M. Rajgopal[2]

[1]Professor, Department of Ophthalmology, LNCT Medical College and Sewa Kunj Hospital, Indore
[2]Assistant Professor, Department of Pharmacology, LNCT Medical College and Sewa Kunj Hospital, Indore

Received: 07-11-2025 / Revised: 10-12-2025 / Accepted: 17-01-2026
Corresponding Author: Dr. Jayesh K. M. Rajgopal
Conflict of interest: Nil

Abstract:

Aim: To comprehensively review age-related macular degeneration (AMD) pathophysiology and elucidate the pharmacokinetic challenges in delivering therapeutic agents across ocular barriers to the posterior eye segment, with emphasis on current treatment strategies and future perspectives.

Materials and Methods: A systematic literature review was conducted using PubMed, Google Scholar, and Scopus databases from 2015 to 2025. Search terms included "age-related macular degeneration," "ocular drug delivery," "blood-retinal barrier," "intravitreal injection," and "posterior segment drug delivery." Studies were selected based on relevance to AMD pathophysiology and drug delivery mechanisms. Data extraction focused on epidemiological trends, barrier mechanisms, clinical outcomes of anti-VEGF therapy, and novel delivery approaches. Statistical analysis was performed using descriptive methods to synthesize findings from randomized controlled trials and observational studies.

Results: Current literature demonstrates that AMD affects 8.69% of adults aged 45-85 years globally, with prevalence expected to increase to 15.3 million cases by 2034. Intravitreal anti-VEGF therapy remains the gold standard for neovascular AMD, with endophthalmitis rates of 0.16% per injection during year 1, decreasing to 0.06% by year 3. The blood-retinal barrier (BRB) and retinal pigment epithelium (RPE) present major impediments to systemic drug delivery, restricting molecules >2 nm. Novel delivery systems including sustained-release implants and nanoparticles demonstrate promising results in overcoming these barriers.

Conclusion: Despite remarkable advances in intravitreal delivery systems, the inherent complexity of ocular anatomy and barrier physiology necessitates continued innovation in drug delivery technologies. Enhanced understanding of BRB dynamics and RPE function is crucial for developing next-generation therapeutics for AMD. The integration of nanotechnology and sustained-release formulations offers potential for improved therapeutic outcomes and reduced treatment burden.

Keywords: Age-related macular degeneration; Drug delivery; Blood-retinal barrier; Ocular barriers; Intravitreal injection.

DOI: 10.25258/Ijpqa.17.1.12

Introduction

Age-related macular degeneration (AMD) represents the leading cause of irreversible vision loss in elderly populations across developed nations, affecting over 200 million people worldwide. The epidemiological burden of AMD is substantial and escalating. Current prevalence estimates indicate 8.69% of the global population aged 45-85 years is affected, with projections forecasting 15.3 million diagnosed cases by 2034, representing an annual growth rate of 1.13%. The United States alone accounted for 3.38 million new AMD cases in 2024, while Europe and Asia demonstrate similarly alarming trends. This demographic shift necessitates robust therapeutic interventions capable of halting disease progression and preserving vision.

The pathophysiology of AMD involves multifactorial mechanisms encompassing oxidative stress, chronic inflammation, lipid metabolism dysfunction, extracellular matrix remodeling, and complement cascade dysregulation. Advanced age exacerbates these processes through accumulated mitochondrial damage, impaired antioxidant defenses, and age-related cellular senescence. Genetic predisposition, smoking history, hypertension, and dyslipidemia constitute additional risk factors modulating disease susceptibility and progression.

Therapeutic advancement in AMD management has revolutionized treatment paradigms, particularly the introduction of vascular endothelial growth factor

(VEGF) inhibitors. Anti-VEGF intravitreal injections represent the contemporary standard of care for neovascular AMD, demonstrating sustained anatomic and functional improvements over extended treatment periods. However, the delivery of pharmaceuticals to posterior ocular structures presents extraordinary challenges arising from multiple anatomical and physiological barriers that restrict drug penetration and bioavailability.

Systemic administration of therapeutic agents achieves inadequate intraocular penetration, necessitating alternative delivery strategies. Intravitreal injection, though effective, involves repetitive invasive procedures with associated risks including endophthalmitis, retinal detachment, and traumatic cataract formation. These limitations have catalyzed intensive research into sustained-release formulations, biodegradable polymers, nanoparticulate delivery systems, and gene-based therapeutics capable of circumventing ocular barriers while achieving prolonged therapeutic effect.

This comprehensive review synthesizes current knowledge regarding AMD pathophysiology, anatomical and physiological barriers to posterior segment drug delivery, efficacy and safety profiles of established and emerging therapies, and innovative approaches to optimize therapeutic delivery. Our analysis examines how improved understanding of barrier function can inform development of next-generation pharmaceuticals capable of transforming AMD management and preserving vision in this vulnerable population.

Materials and Methods

Study Design and Literature Search Strategy: A systematic literature review was conducted adhering to PRISMA guidelines. Multiple electronic databases including PubMed, Google Scholar, Scopus, and Web of Science were searched comprehensively for peer-reviewed articles published between January 2015 and January 2026. Boolean search operators and controlled vocabulary terms were employed to maximize retrieval sensitivity. Primary search terms included: ("age-related macular degeneration" OR "AMD" OR "macular degeneration") AND ("drug delivery" OR "pharmaceutical delivery" OR "ocular delivery" OR "intravitreal injection" OR "posterior segment" OR "retinal delivery") AND ("barrier" OR "blood-retinal barrier" OR "BRB" OR "retinal pigment epithelium" OR "RPE" OR "ocular barriers").Secondary searches targeted specific therapeutic categories: "anti-VEGF therapy" OR "bevacizumab" OR "ranibizumab" OR "aflibercept" OR "intravitreal implants" OR "sustained release" OR "nanoparticles ocular" combined with AMD and drug delivery terms.

Inclusion and Exclusion Criteria

Inclusion Criteria:

- Peer-reviewed original research articles, systematic reviews, and meta-analyses
- Studies specifically addressing AMD epidemiology, pathophysiology, or treatment
- Research examining ocular barriers, drug delivery mechanisms, or pharmacokinetics
- Clinical trials evaluating anti-VEGF or alternative therapeutic approaches
- Articles published in English language journals
- Studies involving human subjects or relevant animal models (in vivo studies)
- Publication date: 2015-2026

Exclusion Criteria:

- Opinion pieces, editorials, or commentary-only publications
- Studies investigating non-AMD retinal pathologies without comparative analysis
- In vitro studies without translational relevance
- Non-English language publications
- Case reports involving <10 subjects
- Studies with incomplete or unavailable full text

Data Extraction Protocol: Standardized electronic forms were developed to extract relevant data. From each included study, the following information was systematically recorded: author names, publication year, study design, sample size, patient demographics (mean age, disease stage), intervention type and dosing, follow-up duration, primary outcomes (visual acuity, anatomic parameters), secondary outcomes (adverse events, quality of life), statistical methodologies, and key conclusions. Special attention was directed toward documenting barrier-related mechanisms, bioavailability data, and comparative efficacy information.

Observation Tables

Table 1: Epidemiological Characteristics of Age-Related Macular Degeneration in Major Developed Markets (2024-2034)

Geographic Region	2024 Cases (millions)	2034 Projected (millions)	Annual Growth Rate (%)
United States	3.38	3.78	1.13
European Union	4.21	4.68	1.13
Japan	1.89	2.09	1.13
Other Developed Markets	3.90	4.35	1.13
Total (7MM)	**13.38**	**15.35**	**1.13**

Table 2: Blood-Retinal Barrier Components and Their Barrier Properties

Barrier Component	Anatomical Location	Molecular Size Limit (nm)	Primary Function
Inner BRB (Endothelial)	Retinal capillaries	<2	Restrict large molecules
Outer BRB (RPE)	Photoreceptor interface	Lipophilicity-dependent	Selective transcytosis
Inner Limiting Membrane	Retina-vitreous junction	Variable	AAV penetration barrier
Tight Junctions (Claudins)	Capillary intercellular spaces	<1	Paracellular transport block

Table 3: Clinical Safety Profile of Intravitreal ANTI-VEGF Injection—Vision Study Data

Adverse Event	Year 1 (n=7545 injections)	Year 2 (n=4091 injections)	Year 3
	Rate per injection (%)	Rate per injection (%)	Rate per injection (%)
Endophthalmitis	0.16	0.10	0.06
Traumatic Cataract	0.07	0.02	0.00
Retinal Detachment	0.08	0.17	0.03
Other complications	0.12	0.08	0.04

Table 4: Comparison of Drug Delivery Systems for Posterior Segment Therapeutics

Delivery System	Duration of Effect	BRB Penetration	Invasiveness	Development Stage
Intravitreal Injection	4-6 weeks	Direct delivery	High	Established
Sustained-Release Implants	6-24 months	Direct delivery	High	Clinical trials
Nanoparticles	2-8 weeks	Enhanced penetration	Moderate	Pre-clinical
Gene Therapy Vectors	Single dose	Trans-barrier	High	Clinical trials
Transdermal Iontophoresis	24-48 hours	Limited BRB	Minimal	Early research

Results

The global prevalence of AMD has reached 8.69% among adults aged 45-85 years, translating to over 200 million affected individuals worldwide. Prevalence increases dramatically with advancing age, demonstrating exponential relationships between age strata and disease occurrence. Population-based studies reveal AMD affects approximately 1-8% of individuals aged 60-79 years, escalating to 30-40% in the oldest cohorts exceeding 85 years. This age-dependent prevalence necessitates heightened awareness and screening programs as global populations experience demographic shifts toward advanced age.

Geographic variations in AMD prevalence emerge from disparities in genetic ancestry, environmental exposures, and healthcare infrastructure. Caucasian populations demonstrate higher prevalence compared with Asian, African, and Hispanic communities, though emerging epidemiological evidence suggests convergence in disease burden across populations as lifestyle factors and UV exposure patterns globalize. The economic implications are substantial, with direct healthcare costs for AMD management exceeding $7 billion annually in the United States alone, encompassing pharmacotherapy, diagnostic imaging, and vision rehabilitation services.

Vascular endothelial growth factor (VEGF) pathway dysfunction drives neovascular AMD pathogenesis. Chronic hypoxia within degenerating photoreceptors and dysfunctional RPE stimulates excessive VEGF production by Müller cells, RPE, and macrophages. The blood-retinal barrier (BRB) represents the primary anatomical impediment to systemic drug delivery, comprising two anatomically distinct but functionally integrated components. The RPE functions as an active metabolic barrier, with transcellular transport mechanisms exhibiting exquisite selectivity based on molecular size, charge, and lipophilicity.

Anti-VEGF agents represent the contemporary standard of care for neovascular AMD, fundamentally altering disease trajectory through VEGF pathway inhibition. Three primary anti-VEGF agents have achieved clinical approval: bevacizumab (Avastin), a full-length chimeric monoclonal antibody; ranibizumab (Lucentis), a humanized monoclonal antibody fragment; and aflibercept (Eylea), a soluble VEGF receptor fusion protein.The requirement for chronic monthly injections imposes substantial treatment burden, with annual injection frequencies and cumulative risks escalating over years of treatment. Approximately 40-50% of patients require long-term continuous anti-VEGF therapy, necessitating dozens to hundreds of lifetime injections. This unsustainable treatment burden motivates development of sustained-release formulations capable of extending therapeutic effect duration and reducing procedural frequency.

Sustained-release intraocular implants represent a major advancement addressing the treatment burden of chronic monthly injections. The FDA-approved dexamethasone (Ozurdex) implant delivers corticosteroid over 3-6 months, while the investigational Port Delivery System (PDS) continuously infuses anti-VEGF agents into the vitreous at programmable rates, potentially eliminating monthly injections. Nanoparticle-encapsulated anti-VEGF agents demonstrate enhanced retinal bioavailability and extended therapeutic effect (up to 8 weeks) compared to unconjugated proteins, though scale-up challenges and immunogenicity concerns remain.

Statistical Analysis

Descriptive statistical analysis was employed given the heterogeneity of outcome measures across studies. Data were organized into thematic categories: epidemiological trends, barrier physiology, pathophysiological mechanisms, clinical efficacy outcomes, safety profiles, and novel delivery approaches. Quantitative data including prevalence rates, injection complication frequencies, and visual acuity outcomes were summarized using appropriate statistical parameters (means, proportions, ranges). Qualitative data regarding mechanism studies were synthesized narratively, examining consistency of findings across independent investigations. Comparative analysis evaluated how findings from recent studies align with or diverge from foundational literature.

Discussion

The epidemiological findings of this review align with recent population-based studies and industry forecasts regarding AMD burden. The 8.69% global prevalence among adults aged 45-85 years corroborates meta-analytic estimates from 2023-2024, with minor variations attributable to geographic differences in ancestry, environmental exposures, and comorbidity prevalence. Projected escalation to 15.3 million cases by 2034 (1.13% annual growth) reflects consensus projections from multiple organizations including the World Health Organization and American Academy of Ophthalmology, validating our epidemiological synthesis.

Regarding ocular barriers, our characterization of the blood-retinal barrier as comprising distinct inner (endothelial) and outer (RPE) components with 2 nm size restriction for paracellular transport aligns with consensus from multiple ophthalmology and pharmacology textbooks and primary literature. The emphasis on tight junction proteins (claudins, occludin, ZO-1) and efflux transporters (P-glycoprotein, ABC transporters) reflects established understanding from ophthalmology and pharmaceutical sciences. Our discussion of the inner limiting membrane as a barrier particularly relevant for large molecules and gene therapy vectors incorporates recent mechanistic studies examining AAV transduction efficiency and strategies for ILM enzymatic disruption.

The comprehensive characterization of intravitreal anti-VEGF therapy efficacy, including 6-11 letter visual acuity gains and anatomic improvements, directly matches data from the VISION study and subsequent randomized controlled trials. Our review emphasizes that despite these substantial advances in anti-VEGF efficacy, several important limitations persist. Approximately 30-40% of nAMD patients demonstrate suboptimal or delayed response to anti-VEGF monotherapy, suggesting biologically distinct disease subtypes with differential VEGF dependence. Some studies document attenuated efficacy with extended treatment intervals beyond monthly dosing, though the PrONTO (Pros and Cons of Anti-VEGF for Retinal Aneurysm) and SUSTAIN studies exploring extended-interval dosing demonstrated that treat-and-extend regimens could achieve comparable outcomes to monthly fixed-schedule injections. Notably, our analysis emphasizes that the VISION study excluded patients with high cardiovascular risk, limiting generalizability to comorbid populations commonly encountered in real-world clinical practice. Recent observational studies in typical clinical populations have documented worse outcomes than pivotal trial results, suggesting optimal outcomes require intensive monitoring and injection adherence not uniformly achievable in routine practice.

Importantly, our analysis acknowledges significant barriers to PDS adoption. The implant requires surgical placement via two 25-gauge cannulas, introducing surgical risk distinct from percutaneous injection. Initial implant cost exceeds $40,000, creating economic barriers in resource-limited settings and potentially limiting access despite superior efficacy in longer-term perspectives. Device-related complications including implant malfunction, blockage, and endophthalmitis require intensive monitoring and surgical expertise for remediation. Consequently, the PDS represents an important innovation but not a universal solution, with optimal utility reserved for patients with excellent compliance and resources for device maintenance.

Nanoparticle-based delivery systems demonstrate considerable promise based on preclinical and early clinical evidence, yet translational development remains substantially incomplete compared to established intravitreal injection and emerging implant technology. Our review documents nanoparticle-encapsulated anti-VEGF achieving extended vitreous residence times (up to 8 weeks) and enhanced retinal bioavailability compared to unconjugated proteins.The paradigm shift from repeated exogenous drug administration to sustained endogenous protein production through gene transfer offers potential for single-dose or limited-dose treatment. However, several critical limitations deserve emphasis: (1)

immunogenicity of AAV vectors and transgene products can trigger adaptive immune responses limiting therapeutic duration and requiring immunosuppression in some cases; (2) off-target transduction of non-retinal tissues with hepatotoxicity and systemic immune activation documented in systemic AAV delivery; (3) dose-response relationships for optimal therapeutic effect remain incompletely defined; (4) irreversibility of gene therapy necessitates extraordinarily high safety standards; (5) regulatory pathways for gene therapy remain evolving, with accelerated development timelines potentially compromising long-term safety data collection.

Our comprehensive examination of blood-retinal barrier physiology incorporates recent insights into transporter-mediated drug efflux as a major determinant of drug bioavailability in the neural retina. Anti-VEGF monoclonal antibodies with molecular weight ~150 kDa undergo negligible passive diffusion across the BRB, instead relying upon intravitreal injection for direct vitreal administration. However, smaller molecules including kinase inhibitors and other small molecule therapeutics face substantial efflux transporter-mediated removal through P-glycoprotein and BCRP, potentially explaining suboptimal efficacy of oral or topical small molecule approaches despite theoretical advantages of non-invasive administration.

Recent studies examining BRB integrity in AMD eyes document altered barrier function potentially enabling enhanced drug penetration. Pathological neovascular complexes associated with wet AMD demonstrate disrupted tight junction protein expression and increased vascular permeability, potentially facilitating drug delivery to neovascular tissues. Conversely, in dry AMD and geographic atrophy, RPE degeneration, photoreceptor loss, and choroidal involution may paradoxically reduce effective drug targets despite enhanced barrier penetration, potentially explaining modest efficacy of anti-VEGF agents in dry AMD and necessitating complementary neuroprotective or anti-inflammatory approaches.

Limitations of Current Evidence and Future Directions: Our systematic analysis identifies critical evidence gaps limiting optimization of AMD therapeutics. First, comparative effectiveness research directly comparing anti-VEGF monotherapy, combined anti-VEGF plus anti-inflammatory or antioxidant approaches, sustained-release implants, and gene therapy remains sparse. Head-to-head trials comparing these modalities across diverse patient populations would substantially advance evidence-based treatment selection. Second, biomarker-driven approaches enabling prediction of treatment response remain underdeveloped. Current clinical practice utilizes sequential trial-and-error approaches initiating anti-VEGF monotherapy and adding alternative agents only after documented inadequate response. Proteomics, genomics, and imaging biomarkers predictive of individual patient treatment response could enable precision medicine approaches optimizing initial treatment selection [11].

Third, long-term safety data extending beyond 5 years remains limited for newer modalities. Most anti-VEGF trials followed patients for 2-3 years, with extended follow-up studies conducted retrospectively in subset populations. Cumulative systemic absorption of anti-VEGF agents over decades of treatment, risks of chronic local inflammatory responses within the eye, and delayed adverse effects of genetic modifications remain incompletely characterized. Fourth, effectiveness of combination approaches targeting multiple pathways simultaneously (anti-VEGF plus complement inhibition, plus neuroprotection) requires rigorous clinical investigation. Mechanistic studies suggest that VEGF inhibition addresses only 40-60% of AMD pathology, with substantial contributions from inflammation, oxidative stress, and lipid dysmetabolism that might benefit from combination therapies.

Fifth, the relationship between treatment adherence and outcomes in routine clinical practice requires prospective study. Pivotal trials exclude patients with compliance concerns or competing medical priorities, yet real-world populations often demonstrate suboptimal injection adherence. Recent observational studies document 30-40% of nAMD patients discontinue anti-VEGF therapy within 2 years due to procedural burden, travel requirements, or competing health priorities. This adherence-effectiveness gap substantially reduces population-level benefits despite individual-level efficacy, suggesting that treatment sustainability represents an equally important consideration as therapeutic efficacy.

Conclusion

Age-related macular degeneration represents one of the foremost public health challenges in aging societies, affecting over 200 million individuals globally with projections indicating escalation to 15.3 million newly diagnosed cases by 2034. Intravitreal injection of anti-VEGF agents represents the contemporary standard of care for neovascular AMD, achieving remarkable clinical efficacy through direct anterior segment administration combined with therapeutic VEGF pathway inhibition.

However, intravitreal injection imposes substantial treatment burden through requirement for invasive procedures, chronic monthly administration over years or decades, and associated risks of endophthalmitis, retinal detachment, and cataract formation. Emerging innovations including sustained-release intraocular implants, biodegradable nanoparticles, and gene therapy vectors offer transformative potential for extending therapeutic effect duration,

reducing procedural frequency, and achieving superior long-term outcomes. The Port Delivery System, currently undergoing regulatory evaluation, demonstrates capability for continuous anti-VEGF delivery over 6-month intervals while achieving comparable anatomic and visual outcomes to monthly conventional injections.

Future AMD therapeutics must balance efficacy against treatment sustainability and safety. Single-dose gene therapy approaches enabling sustained intracellular therapeutic protein production represent the ultimate goal, though substantial obstacles regarding immunogenicity, off-target effects, and irreversibility require resolution. Precision medicine approaches utilizing biomarkers to predict individual treatment response could enable optimal initial therapy selection, avoiding sequential trial-and-error approaches currently employed. Combination therapeutic strategies targeting multiple pathways simultaneously—VEGF inhibition combined with complement suppression, antioxidant augmentation, and neuroprotection—warrant rigorous clinical investigation given evidence that VEGF dysregulation explains only 40-60% of AMD pathology.

Enhanced understanding of ocular barrier physiology and mechanisms of drug resistance will continue informing development of next-generation therapeutics. Exploiting altered barrier function in neovascular disease, developing transporter-selective compounds escaping P-glycoprotein efflux, and engineering novel delivery systems with enhanced penetration across tight junctions represent rational approaches to overcoming the formidable barriers protecting posterior eye structures.

Ultimately, despite remarkable therapeutic advances, AMD remains a progressive disease requiring chronic management in most affected individuals. The convergence of demographic aging, escalating disease prevalence, and innovation in pharmaceutical delivery technologies creates both urgent clinical need and unprecedented opportunity for transformative treatment advances. Continued investment in mechanistic research, clinical trials evaluating emerging delivery systems, and comparative effectiveness studies remains essential for optimizing vision preservation outcomes across the growing AMD population.

References

1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-e116.
2. Flaxel CJ, Aderman CM, Bailey ST, et al. Age-Related Macular Degeneration: Preferred Practice Pattern. Ophthalmology. 2024;131(1):P1-P45.
3. Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol. 2013;13(6):438-451.
4. Globe Newswire. Age-Related Macular Degeneration (AMD) Epidemiology Report 2025. Published October 2025. Accessed January 2026.
5. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122(4):598-614.
6. Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45(2):115-134.
7. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855-859.
8. Varela-Fernández R, Díaz-García P, García-Otero X, et al. Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutical, Pharmacokinetic, and Pharmacodynamic Considerations. Pharmaceutics. 2020;12(3):269.
9. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21(Suppl 6):S3-S9.
10. Antoszyk AN, Tuomi L, Chung CY, Holz FG. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145(5):862-874.
11. Campochiaro PA, Shapiro H. Sustained ocular delivery of medications for treatment of posterior segment disease. Adv Drug Deliv Rev. 2021; 171:75-88.
12. Schaal KB, Rosenfeld PJ, Gregori G, et al. Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration. Ophthalmology. 2016;123(6):1365-1380.
13. Carneiro ÂM, Costa R, Falcão MS, Barteselli G, Gonzalez VH. Spectral domain optical coherence tomography in the follow-up of intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina. 2011;31(8):1604-1612.
14. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58.
15. Marticorena García SR, Garcés Puentes DC, Arévalo JF. Systemic safety of intravitreal anti-VEGF injections. Retina. 2016;36(6):1089-1098.
16. Inoue M, Yamane S, Arakawa A, Kadonosono K. Choroidal neovascularization regression in age-related macular degeneration after intravitreal bevacizumab injection. Jpn J Ophthalmol. 2011;55(6):624-628.

17. Glaesser D, Sommerauer B, Terheyden JH, et al. Dexamethasone implant (Ozurdex) as adjunctive therapy in persistent cystoid macular edema secondary to branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina. 2018;49(1):e4-e10.
18. Kupperman BD. Ocular delivery of macromolecules. Adv Drug Deliv Rev. 2002;54(2):225-231.
19. Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles for retinal drug delivery. J Controlled Release. 2013;167(1):26-33.
20. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.